Clinical Trial Detail

NCT ID NCT03243331
Title An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kathy Miller
Indications

triple-receptor negative breast cancer

Therapies

Cofetuzumab pelidotin + Gedatolisib

Age Groups: adult senior

No variant requirements are available.